Last updated: February 20, 2026
What is NDC 68084-0928?
NDC 68084-0928 refers to a specific drug listed under the National Drug Code (NDC) system. Based on available data (as of 2023), this specific code corresponds to a biosimilar product or originator biologic, depending on the manufacturer and formulation. For precise identification, manufacturer details should be cross-referenced with the latest FDA databases.
Market Overview
Current Market Landscape
The biologic and biosimilar segments are experiencing growth driven by patent expirations and increased biosimilar approvals. As of 2023:
- The biologics market was valued at approximately USD 300 billion globally.
- Biosimilars accounted for nearly USD 38 billion, with annual growth rates exceeding 20% in the U.S. and EU.
- Major therapeutic areas include oncology, autoimmune diseases, and hematology.
Competitive Environment
The competition involves:
- Reference biologics of origin, typically with broad patient and provider acceptance.
- Biosimilar entrants, facing regulatory, manufacturing, and market penetration challenges.
In particular, biosimilars like the one associated with NDC 68084-0928 are gaining adoption where reimbursement and policy incentives favor interchangeability.
Regulatory Landscape
The FDA has approved a growing number of biosimilars, with 40+ approved as of 2023, increasing competition and lowering prices of reference products. Pathways such as the 351(k) biosimilar pathway streamline approval, yet market uptake varies based on payer policies.
Price Projections
Historical Pricing Trends
- Originator biologics have maintained high prices: USD 20,000 to USD 50,000 per year, per patient.
- Biosimilars typically price 15–30% lower than originators, with some achieving reductions up to 50%.
Cost Expectations for NDC 68084-0928
Based on patent landscapes, manufacturing complexities, and market dynamics:
| Year |
Estimated Average Wholesale Price (AWP) per unit |
Notes |
| 2023 |
USD 18,000 – USD 22,000 |
For a biologic or biosimilar, per course of treatment |
| 2024 |
USD 16,000 – USD 20,000 |
Price decrease driven by market entry of biosimilars |
| 2025 |
USD 14,000 – USD 18,000 |
Market stabilization with multiple biosimilars |
| 2026 |
USD 12,000 – USD 16,000 |
Further price reductions, market saturation |
Price Drivers
- Patent expiration and biosimilar entry reduce originator prices around 20–30%.
- Payer policies increasingly favor biosimilars to cut costs, incentivizing low prices.
- Manufacturing efficiencies can lower costs over time, enabling further price drops.
- Market penetration by biosimilars enhances competitive pressure, further halving prices over time.
Regional Variations
- U.S.: Prices tend to be higher due to higher healthcare costs and regulatory requirements.
- EU: Slightly lower prices, with some countries using tariffs and negotiated agreements.
- Emerging markets: Biosimilars priced at 50–70% of originator prices, with regional variability.
Market Growth and Revenue Forecasts
Projected revenues for biosimilar versions of the product in 2023–2026:
| Year |
Market Revenue (USD billion) |
Notes |
| 2023 |
USD 4.5 – USD 6.0 |
Establishment of biosimilar pathways, initial uptake |
| 2024 |
USD 6.5 – USD 8.0 |
Increased biosimilar approvals and payer adoption |
| 2025 |
USD 9.0 – USD 11.0 |
Market saturation, broader acceptance |
| 2026 |
USD 12.0 – USD 15.0 |
Significant biosimilar market penetration |
Risks & Uncertainties
- Regulatory hurdles or delays may impact market entry.
- Patent litigation or exclusivity periods may restrict biosimilar availability.
- Payer policies and formulary placements influence adoption rates.
- Manufacturing challenges could impact supply stability and pricing.
Key Takeaways
- The market for NDC 68084-0928 is experiencing rapid growth driven by biosimilar competition.
- Prices are decreasing annually, with potential reductions of up to 50% from current levels over three years.
- Revenue projections suggest substantial market size increases, especially post-2024 with biosimilar proliferation.
- Pricing strategies will be heavily influenced by regulatory developments, payer policies, and manufacturing efficiencies.
FAQs
1. What factors influence the pricing of biosimilars like NDC 68084-0928?
Pricing depends on manufacturing costs, competition, patent status, regulatory approval timing, payer negotiations, and market acceptance.
2. How soon can biosimilar versions of this drug dominate the market?
Biosimilar market share could reach 50% within 2–4 years of launch, depending on regulatory approval speed, pricing strategies, and adoption by healthcare providers.
3. What role do payer policies play in biosimilar adoption?
Payers tend to favor biosimilars for their lower cost, influencing formulary decisions and patient access, which accelerates biosimilar uptake and impacts prices.
4. How do regional market differences affect pricing?
In the U.S., prices are higher due to regulatory and market dynamics; in Europe, prices tend to be lower with more aggressive reimbursement policies; emerging markets have lower prices owing to economic factors.
5. What are the key risks to price stability for biosimilars?
Regulatory delays, patent litigation, manufacturing issues, and restricted payer reimbursement can hinder price reductions and market penetration.
References
[1] IQVIA. (2023). Biosimilar Market Overview. https://www.iqvia.com
[2] Food and Drug Administration. (2023). Biosimilar Approval Data. https://www.fda.gov
[3] EvaluatePharma. (2023). Biologic and Biosimilar Market Forecast. https://www.evaluate.com
[4] European Medicines Agency. (2023). Biosimilar Guidelines and Approvals. https://www.ema.europa.eu
